Microelectromechanical systems (mems) for drug delivery:

A detailed Review

Suyash Ingle*, Kshitij Shinde, Aniruddh Kurulkar

Solapur, Maharashtra India.

*Corresponding Author E-mail: suyashingle07@gmail.com, shindekshitij20@gmail.com

ABSTRACT:

To enhance medical care and medication administration, a rapidly expanding area of bioengineering and biotechnology called microelectromechanical systems, or MEMS, combines mechanical and microelectronic components. These technologies enable more precise and targeted medicine administration, reducing side effects and increasing therapeutic efficacy. MEMS devices are incredibly adaptable and small, and they may find application in a variety of fields, such as communications, electronics, and medicine. Through wearables or implants, MEMS can be utilized in medical applications to treat diseases including diabetes, cancer, heart disease, and neurological issues by delivering medication directly to the site of need. These devices, which also offer benefits like precision dosing, remote monitoring, improved patient compliance, and tailored therapy, can be used to give small molecules and biologics. Implantable medical devices have a bright future ahead of them thanks to the significantly expanded possibilities of nanotechnology and wireless connectivity together. Notwithstanding, there are still obstacles to overcome, such as the necessity for additional miniaturization, regulatory obstacles, intricate production procedures, integration and packaging constraints, and environmental sensitivity. To fully realize the potential of MEMS in medical and other applications, concerns including long- term dependability, cost reduction, standardization, and scaling up production must also be addressed. Despite these obstacles, MEMS devices have the potential to completely transform healthcare and other industries by providing accurate, customized, and effective solutions.

KEYWORDS: MEMS, Drug Delivery, Therapeutic efficacy

INTRODUCTION:

It is becoming more and more important to develop innovative drug delivery systems due to the quick progress in pharmaceutical research. Traditional drug delivery techniques, like oral or intravenous administration, frequently fall short of meeting the wide range of requirements of contemporary drug candidates. Modern medications' diverse molecular types and characteristics, such as large biomolecules with low bioavailability, small molecules with poor solubility, and powerful drugs with limited therapeutic windows, necessitate this. It's possible that the conventional administration techniques can't effectively address these different attributes, which means that novel delivery systems will be needed.

Historical context:

Simple techniques such as intravenous injections and oral pills have dominated drug administration. Although oral administration is convenient, it is frequently constrained by problems such as sensitive drugs' volatility in the gastrointestinal tract and big molecules' low bioavailability. Although intravenous injection has a high bioavailability and is effective for fast drug delivery, many current therapies require more precision and control. As the pool of potential drugs grew, the shortcomings of these old-fashioned approaches became more obvious, prompting the creation of more sophisticated drug delivery systems.

A notable change is the introduction of medication delivery technologies like microtechnology and nanoparticle- based systems. Innovation has been primarily motivated by the desire to overcome physiological limitations and achieve tailored delivery. Nanoparticles were developed to solve problems.

Advantages of Novel Drug Delivery Systems:

A) Nanoparticle-based frameworks:

· Targeted Delivery: Drug efficacy and side effect reduction can be achieved by engineering nanoparticles to specifically target cells or tissues. For example, medications can be delivered directly to the brain using nanoparticles, which can pass through physiological barriers such as the blood-brain barrier (BBB).

· Controlled Release: By keeping medication levels within the ideal range over time, they can be made with controlled or sustained release in mind, which improves therapeutic outcomes.

· Improved Solubility: By making poorly soluble medications more soluble, nanoparticles can effectively administer them orally or through other means.

B) Microtechnology (MEMS):

· Accuracy and Regulation: MEMS technology accurately regulates medication administration volumes and rates. Drugs can be administered under control using micro pumps and microneedles, which lessens the need for diffusion and allows for more precise dosing.

· Minimally Invasive: By decreasing patient discomfort and enhancing compliance, microneedle technology provides a less invasive substitute for conventional injections.

· Integration with Electronics: Wireless transmission and real-time data-driven drug delivery changes are made possible by the integration of MEMS devices with electronic controllers for smart drug release.

Disadvantages and Challenges:

A) Nanoparticle-based frameworks:

· Complex Manufacturing: It is an expensive and time-consuming procedure to encapsulate medications within nanoparticles while guaranteeing stability and controlled release. Scalability and consistency in manufacturing can be difficult to achieve.

· Biodistribution Issues: A detailed assessment is necessary to determine the biodistribution and possible toxicity of nanoparticles. They might gather in unexpected places and have negative consequences.

· Regulatory Obstacles: Strict regulatory criteria for novel drug delivery systems might cause delays in their development and approval.

B) Microtechnology (MEMS):

· Technical Complexity: Advanced technology and knowledge are needed for the design and construction of MEMS devices. It might be difficult to guarantee functioning and dependability in real-world applications.

· Biocompatibility: To prevent unfavorable responses in the body, the materials employed in MEMS devices must be biocompatible. A thorough evaluation of these materials' long-term safety is necessary.

· Cost: The high cost of the sophisticated materials and technologies used in MEMS may raise the overall cost

Ideal Characteristics of Novel Drug Delivery Systems:

1. Targeted Delivery:

To reduce off-target effects and enhance therapeutic outcomes, the system should deliver medications exactly to the targeted site of action. This is important for treating disorders that are limited to a certain area or organ.

2. Release under Control:

A perfect system should provide a regulated or sustained release of the medication, lowering the frequency of administration and maintaining therapeutic levels for a longer amount of time.

Safety and Biocompatibility: To protect patients and reduce side effects, medication delivery systems need to be made of non-toxic, biocompatible materials.

3. Accuracy and Efficiency:

Precise control over medication delivery quantities and rates should be possible with the system, enabling precise dosage and customization to meet the demands of each patient.

4. Minimally Invasive:

When compared to conventional methods, minimally invasive delivery techniques, such as those utilizing microneedles, can improve patient comfort and compliance.

5. Economy of Scale:

Although the initial prices of sophisticated technology may be greater, it is important to evaluate their eventual cost-effectiveness, taking into account possible advantages like fewer hospital visits and better treatment results.

Current Challenges and Future Directions:

Depending on the drug candidates and target locations, several obstacles must be addressed in the development of improved drug delivery systems. For instance, getting past physical obstacles like the BBB and BRB is necessary when aiming at the brain or posterior eye segment. Systems based on nanoparticles are being developed to tackle these issues, although the primary difficulties still lie in minimizing possible adverse effects and guaranteeing efficient delivery. In transdermal medication administration, the goal is now to precisely manage the duration of drug dosing rather than just breaking through the stratum corneum barrier. The goal of developing enhanced transdermal patches is to offer choices for regulated and flexible release, supporting different treatment plans including continuous or intermittent doses.

It is expected that future developments in medication delivery systems will concentrate on resolving the outstanding issues and incorporating new technology. To create systems that can adapt to the changing demands of contemporary medicine, materials science, microtechnology, and nanotechnology research and innovation must continue.

Key Concepts:

Fig. 1: Key concepts of MEMS

The goal of Micro-Electro-Mechanical Systems (MEMS) technology is to precisely and miniaturize mechanical and electrical components with sizes between micrometers and millimeters. MEMS devices can measure, control, and manipulate physical quantities with exceptional accuracy because of sophisticated fabrication techniques including photolithography and etching. MEMS, which are widely employed in industries including consumer electronics, biomedical devices, and sensors, allow for advancements like lab-on-a-chip diagnostics and accurate motion sensing in smartphones. Notwithstanding difficulties in choosing and producing materials, continuous developments—such as fusion with nanotechnology and bio-MEMS—keep these small, adaptable devices' potential from growing.

Implantable drug delivery systems (IDDS) distribute medication to specific bodily tissues at controlled dosages utilizing micropumps. Systems of Micro-Electro-Mechanical These systems provide efficiency and safety with biocompatible materials like medical-grade silicone and PDMS, which are powered by rechargeable power supply. Essential to IDDS, micropumps distribute medications at exact rates using mechanical or non- mechanical actuation techniques like piezoelectric or magnetic mechanisms. These systems require microfluidics, which is fundamental to the efficient handling of small fluid volumes needed for medication administration and other applications in biomedical diagnostics. Although encouraging, difficulties with scalability for wider applications, material compatibility, and complexity of manufacture exist.

A lab-on-a-chip is a tiny device combining several laboratory procedures onto one platform to quickly and accurately analyze chemical and biological samples. Its origins are in microfluidics, which manages minuscule fluid volumes for use in chemical synthesis, diagnostics, and DNA analysis, among other fields Because lab-on- a-chip technology reduces test prices, time, and resource requirements, it has revolutionized sectors such as biotechnology and pharmaceuticals. It is an essential breakthrough for point-of-care diagnostics and cutting- edge medical research since it has great potential in fields including genome sequencing, pathogen detection, and personalized medicine.

By combining sensors and smartphone apps to track and log inhaler usage, smart inhalers—improved by the Internet of Things—address long-term respiratory conditions including COPD and asthma. By offering real- time feedback and data analysis, these devices minimize clinical severity, optimize treatment, and forecast asthma episodes. Ninety percent of inhaler solutions still have issues that impact patient care and costs, even if they have the potential to enhance patient adherence and results. A viable option for improved illness management, fewer hospital admissions, and more efficient respiratory care by guaranteeing appropriate use and enabling customized therapy.

By fusing tiny mechanical and electrical systems with precise material manipulation, nanotechnology and MEMS (Micro-Electro-Mechanical Systems) can be used to create extremely sophisticated devices at the nanoscale. The healthcare and biotechnology industries benefit greatly from this synergy, which makes breakthroughs like molecularly focused medication delivery systems, implantable diagnostic instruments, and nanoscale sensors possible. By combining these technologies, complex medical problems should be solved more quickly and accurately, revolutionizing patient care, diagnostics, and medications with never-before-seen accuracy and precision.

Applications:

MEMS technology is used in several medical specialties, such as cardiology, neurology, diabetes care, and oncology. They may transport a broad variety of medications, including biologics like proteins peptides, and tiny compounds.

1. Diabetes Management: Insulin Pumps: By imitating the body's natural insulin release, MEMS-based insulin pumps can provide insulin with extreme precision. These gadgets lessen the frequency of injections and enhance glucose control.

2. Oncology: (Chemotherapy) MEMS devices can transport medications intended for chemotherapy directly to the areas of tumors, minimizing harm to healthy tissues and minimizing side effects. Targeted Therapy: They make it possible to precisely deliver therapeutics to cancer cells, like kinase inhibitors and monoclonal antibodies. (Applications: MEMS technology is useful in several medical specialties, including cardiology, neurology, diabetes care, and oncology.

3. Neurology: Deep Brain Stimulation (DBS): By delivering electrical impulses to particular brain regions, MEMS-based DBS systems may be able to treat illnesses like epilepsy and Parkinson's disease. (Drug Delivery to the Central Nervous System: Because of the blood-brain barrier, it is difficult to administer medications to the brain or spinal cord using conventional delivery techniques. MEMS devices, however, can be used to do so.

4. Cardiology: (Drug-Eluting Stents: Direct drug release into the arteries via stents thanks to MEMS technology reduces the risk of restenosis and increases the efficacy of angioplasty treatments.

5. Women's Health: MEMS-based contraceptive implants offer women long-term birth control choices by releasing hormones at a controlled rate.

6. Pain Management: Intrathecal Drug Delivery: MEMS devices can directly administer painkillers into the cerebrospinal fluid of the spinal cord, reducing chronic pain.

7. Ophthalmology: (Glaucoma Treatment: Medication for glaucoma can be injected into the eye using MEMS- based implants, which guarantee reliable drug administration and lower intraocular pressure.

8. Respiratory Diseases: MEMS technology can enhance the accuracy of medication delivery for ailments such as asthma and chronic obstructive pulmonary disease (COPD) using inhalers and nebulizers.

9. Gastrointestinal Disorders: (Medicine Delivery to the Gastrointestinal Tract: MEMS devices can provide medication to certain GI tract sites, improving the management of diseases such as ulcerative colitis or Crohn's disease.

10. Management of Infectious Diseases: (Antibiotic Delivery: MEMS devices can locally provide antibiotics to infection locations, lowering the danger of systemic.

11. Management of Pain and Inflammation: (Intra-articular drug delivery: MEMS-based devices can be utilized to administer specific drugs to joints in diseases such as osteoarthritis.

12. Paediatrics: (Medicine Delivery: MEMS devices can be modified for younger children to guarantee precise dosage and lessen injection discomfort.

13. Transdermal drug delivery Systems: Application Transdermally The limits of traditional transdermal medication administration are addressed by microneedle technology, which was also invented using MEMS. It works by forming micro-pathways through the stratum corneum, the outermost layer of skin. - Solid Durable Microneedles: Produce micro punctures to improve skin permeability are among the types of microneedles. Medication can be applied to needles by coating them or applying patches. *Solid Degradable Microneedles: These microneedles dissolve in the skin to release medication since they are made of biodegradable polymers filled with drugs.

14. Hollow Microneedles: These have structurally less stable bores that allow for direct drug distribution from a reservoir in bigger amounts.

15. Oral drug delivery Systems: Oral Medication Administration Oral administration is still the most often chosen mode of medication administration. Since the beginning of medical science, a great deal of study has gone into creating different oral pills and capsules that can be used to treat a variety of illnesses. Even with these efforts, it is still difficult to administer drugs through this route precisely and optimally. Several physiological obstacles, including mucus, stomach pH, and gastrointestinal tract enzymes, limit the full therapeutic efficiency of medications taken orally.

Fig. 2: Some instruments used in MEMS

Research on MEMS:

Based on MEMS research Medicine administration from micro reservoirs has been studied in the past using transient valves. Designed to shut off sections of drug-filled reservoirs, these metal-film valves serve this purpose. Drug release on demand could be facilitated by selectively activating the valves through current- induced melting or electrochemical dissolution. For longer treatment durations, this technique enabled perfect control over drug distribution. Relatively large amounts (~200 µL) were delivered on demand from pressurized reservoirs using an efficient gate system. The valve design had to be energy-efficient, lightweight, and compact for applications involving small animals like mice. This was accomplished by integrating a Parylene C polymer valve with standard intravenous catheters.

A resistive metallic element (Pt) placed in the valve membrane was activated by pulses of current. As a result, the polymer membrane quickly melted due to Joule heating, allowing pressurized fluid to escape the reservoir. A design that maximized heat transmission during valve activation was one of the later enhancements. It was discovered that current ramping is essential to the efficient operation of liquid valves. To increase the current delivered by inductive power transfer gradually, a thermistor was added in series with the valve. Improvements in the thickness of the valve membrane, trace geometry, and resistive trace material increased mechanical robustness and allowed for dependable valve operation.

A fully implanted electrolysis-based drug delivery pump is a breakthrough for research on drug addiction, managing chronic diseases, and assessing novel therapies. This device, which may be implanted in mice, rats, and rabbits, is made up of a valved delivery cannula attached to an electrolytic actuator that is housed inside a drug reservoir. To push the medication through the cannula, the actuator creates pressure. When a particular pressure threshold is met, the pressure-responsive valve stays closed, enabling targeted drug administration at the treatment.

a. Actuators for Electrolysis in Drug Delivery* Because of their excellent performance, simple design, and low power consumption, electrochemical actuators are a good fit for implanted medication delivery. Chip-based platforms have been used to demonstrate controlled fluid pumping and dosing, and small-scale electrochemical infusion pumps for the delivery of analgesics have been detailed. For the delivery of drugs into the eyes, small form factor electrochemical pumps have been thoroughly investigated. Two methods of delivery were used: a chamber-based system in which the drug is electrolyzed inside a flexible-walled chamber to produce hydrogen and oxygen gases for pneumatic pumping, and direct electrolysis of the drug. The latter mode achieves huge deflections with low power consumption and good efficiency by coupling pneumatic pressure to the drug in a neighboring compartment through the use of a Parylene bellows actuator.

b. Chronic Delivery Using Refillable Reservoirs Long-term medication delivery is necessary for many applications, yet compact devices sometimes don't have refill capability. For example, once depleted, ocular sustained-release implants such as Retisert® or Posurdex® must be replaced, a process that entails multiple surgeries and accompanying hazards. Refillable reservoirs, which enable medication replenishment via a non- coring needle, were incorporated into the delivery platform to address this. According to institutional permission and ethical norms, this method allowed for monthly refills for six months in rabbits during animal investigations.

c. Control of Flow Precise control of flow is essential for safe and efficient drug administration. It is advantageous to have a regulating valve with bandpass properties to stop unintentional dosing at different pressures. Furthermore, a variable fluidic resistor can withstand variations in pressure while maintaining a steady flow rate. The delivery cannula was equipped with these components, which were packaged using heat- shrink tubing of medical grade to hold the parts in place without the need for adhesives.

MEMS Drug Control:

The demand for patient-specific medicine administration therapy has increased over the previous 20 years, leading to the development of more complex and precise drug delivery systems. By incorporating closed-loop feedback systems, pump performance can now be tracked in real-time. Physical sensors can provide vital information on characteristics including pressure, flow rate, dosage size, and pump status. For example, Medtronic's FDA-approved MiniMed 530G with Enlite combines insulin pump therapy with continuous glucose monitoring. This gadget automatically stops delivering insulin when blood glucose levels drop below a predetermined level.

The Minneapolis-St. Paul, Minnesota-based company Medallion Therapeutics, Inc. is leading the way in the development of an implantable medication delivery system with pressure sensor monitoring. Clinical trials are being conducted on this pump to assess how well the pressure sensors work.

Failures in many of the drug delivery systems currently in use are frequently discovered only after the patient experiences physical side effects. Solenoid plungers, piezoelectric elements, electrostatic forces, thermopneumatic systems, and electromagnetic components are a few examples of actuation methods for active valves. A microvalve's design or selection must take into account several factors, such as dead volume, leakage under reverse pressure, flow resistance, size, response time, power consumption, and power consumption. Although active valves offer improved performance, their complexity, and high manufacturing costs frequently place limitations on them.

For example, piezoelectric microvalves have been used in drug delivery pumps to control fluid flow rates. Drug flows from two distinct pressurized reservoirs were controlled and mixed using a dual-valve system that made use of piezoelectric technology. Piezoresistive pressure sensors included in the MEMS valves controlled the flow rates through these microvalves, allowing a range of 0.51 to 2.30 mL/h. For fluid rectification, a phase- change micropump with two passive aluminum flap check valves was also created. At zero flow rate, it could achieve a maximum flow rate of 6.1 µL/min and a maximum back pressure of 69 kPa.

Fig. 3: Piezoelectric microvalve

Challenges:

MEMS devices face several challenges, including long-term reliability, manufacturing complexity, integration, miniaturization restrictions, packaging, power management, biocompatibility, cost reduction, standardization, environmental sensitivity, regulatory challenges, and scaling up production. Reliability is crucial for MEMS components since they are subjected to harsh environmental conditions, necessitating complex microfabrication techniques throughout production. It can be challenging to integrate MEMS devices into larger circuits or systems, thus standardization and compatibility with existing technologies are essential. Since incredibly small devices may have worse sensitivity, reliability, and manufacturing yield, miniaturization can potentially be a restriction. For MEMS devices to remain functional and protect themselves from the environment, proper packaging is essential. Energy-efficient power management methods are needed for battery-powered applications. In biological applications, biocompatibility is essential to prevent unpleasant reactions.

While mass manufacturing relies heavily on cost reduction, early development, and fabrication costs may be unaffordable. Standardization is essential for comparing and assessing performance across devices and manufacturers. Environmental sensitivity is a need for MEMS devices, and meeting regulations can be challenging, especially in the automotive and healthcare industries. Because manufacturing must maintain consistent quality and output, scaling up is very challenging. Solving these issues requires ongoing research, interdisciplinary collaboration, and innovative material, production, and design methodologies.

Future Perspective:

Improved drug delivery technologies are becoming commercially viable thanks to developments in several fields, including materials science, artificial intelligence (ANN), wireless communication, MEMS and NEMS, information technology, and systems biology. These innovations have the power to significantly raise the standard of pharmaceutical-based medical care. The main goal of improved drug delivery systems is to do away with the need for repeated parenteral injection; however, given the expense and complexity of device-based methods, it is unlikely that using an improved delivery device will offer a meaningful benefit. NEMS-based devices are currently in the early stages of study because medication potency limits the minimum size of an implant for continuous administration. It is expected that advances in nanotechnology for medicine delivery will come gradually. By applying the growing capabilities of information technology to personalized distribution, personalized medicine, and drug administration.

It may be possible to achieve feedback loops between medicine dosage control and biosensors. In integrated systems, wireless communication gives designers more flexibility by enabling the physical division of equipment into modules without sacrificing system functionality. An artificial pancreas that combines insulin administration, glucose monitoring, mathematical models, and sampling could be highly helpful to diabetics. The future development of innovative drug delivery combination solutions is expected to be aided by the mix of contemporary technology and accommodating regulatory guidelines.

CONCLUSION:

Small systems known as micro-electro-mechanical (MEMS) systems integrate optical, electrical, and mechanical components to perform a range of functions. These devices are ideal for applications where size and weight constraints are severe because of their excellent miniaturization. Numerous industries, including healthcare, automotive, telecommunications, and consumer electronics, use MEMS devices. With MEMS DDS, you may precisely manage the dosage, release rate, and timing of your medication, increasing its therapeutic efficacy and lowering its side effects. Owing to their compact size, they can be administered by minimally invasive techniques, thereby reducing patient discomfort and the risk of infection. They can be externally applied or implanted to automate the delivery of medications, reducing patient compliance, and systemically systems known as micro-electro-mechanical (MEMS) systems integrate optical, electrical, and mechanical components to perform a range of functions.

CONSEQUENCES:

Certain MEMS DDS systems offer real-time monitoring, which makes it possible to use adaptive dosing strategies and, if required, initiate early intervention. MEMS DDS holds particular promise for long-term medication regimens required for chronic conditions. MEMS DDS has problems with power supply, biocompatibility, and regulatory approval, despite its potential. If public adoption is to happen, these issues need to be resolved.

REFERENCES:

1. Muhammad Waseem Ashraf, Shahzadi Tayyaba, Asim Nisar, and Nitin Afzulpurkar, "MEMS-Based System for Drug Delivery”, 2010 6th International Conference on Emerging Technologies (ICET), pp. 82–87, IEEE 2010.

2. Eric E. Nuxoll and Ronald A. Siegel, “BioMEMS Devices for Drug Delivery”, Improved Therapy by Design, IEEE Engineering in Medicine and Biology Magazine, pp. 31–39. IEEE January/February 2009.

3. Smitha M. N. Rao, Amit Mhatre, Dan O. Popa, J.-C. Chiao, Thermpon Ativanichayaphong, Jeongsik Sin, and Harry E. Stephanou, “MEMS-based Implantable Drug Delivery System”, VII International Conference on Micro Electro Mechanical Systems, Sept. 21–22, 2005, Mexico.

4. P. K. Campbell, K. E. Jones, R. J. Huber, K. W. Horch, and R. A. Normann, “A silicon-based, threedimensional neural interface: manufacturing processes for an intracortical electrode array”, IEEE Trans Biomed Eng 38(8), pp. 758–768.

5. Wang B, Chu X, Li E, and Li L., “Simulations and analysis of a piezoelectric micropump”, Ultrasonic, 44, pp. 643–6, 2006.

6. C. Amy, et al., A BioMEMS review: MEMS technology for physiologically integrated devices, in: Proceedings of the IEEE 921, 2004, pp. 6–21.

7. Zengerle, M. Richter, and H. Sandmaier, A micro membrane pump with electrostatic actuation, in: Proceedings of IEEE, Microelectromechanical System, 92, pp. 19–24.

8. N. Wilke, C. Hibert, J. O’Brien, and A. Morrissey, “Silicon Microneedle electrode array with temperature monitoring for electroporation”, Sensors and Actuators A 123–124, pp. 319–325, 2005.

9. S. Zimmermann, J.A. Frank, D. Liepmann, and A.P. Pisano, A planar micropump utilizing thermo pneumatic actuation and in-plane flap valves, in Proceedings of the 17th IEEE International Conference on Micro Electro Mechanical Systems (MEMS): MEMS 2004 Technical Digest, Maastricht, 2004, pp. 462–465.

10. S.R. Hwang, W.Y. Sim, D.H. Jeon, G.Y. Kim, S.S. Yang, J.J. Pak, Fabrication and test of a sub-microliter-level thermo pneumatic micropump for transdermal drug delivery, in Proceedings of the 3rd Annual International IEEE EMBS Special Topic Conference on Microtechnologies in Medicine and Biology, Kahuku, Oahu, Hawaii, 2005.

11. Hilton P, McMullen JN; A New Gradient Matrix: Formulation and Characterization, Controlled Release; 1995, 34: 263–271.

12. Lu S., Ramirez F., and Anseth K., Photopolymerized, Multilaminated Matrix Devices with Optimized Non-Uniform Initial Concentration Profiles to Control Drug Release, J. Pharm. Sci.; 2000, 89.

13. Qiu Y, Chidambaram N, Flood K; Design and Evaluation of Layered Diffusional Matrices for Zero-Order Sustained Release, J. Controlled Release; 1998, 51: 123–130.

14. ChienYie W., Novel Drug Delivery System, Marcel Dekker Inc., 1992, 2: 381.

15. Saettone MF, Salminen L; Ocular Inserts for Topical Delivery, Adv Drug Del Rev; 1995; 16: 95–106.

16. Khar RK, Vyas SP; Targeted and Controlled Drug Delivery Novel Carrier Systems, CBS Publishers and Distributors: New Delhi; 2002, 1st Ed, 384.

17. A.C. Hunter et al., Smart polymers in drug delivery: a biological perspective Polym. Chem.(2017).

18. R. Fernandes et al., Self-folding polymeric containers for encapsulation and delivery of drugs, Adv. Drug Deliver. Rev. (2012).

19. Y.-C. Kim et al., Microneedles for drug and vaccine delivery, Adv. Drug Deliver. Rev. (2012).

20. M. Aryal et al., Ultrasound-mediated blood-brain barrier disruption for targeted drug delivery in the central nervous system, Adv. Drug Deliver. Rev. (2014).

21. B. Z. Yang and Q. Lin, "A planar compliance-based self adaptive microfluid variable resistor," Journal of Microelectromechanical Systems, vol. 16, pp. 411-419, 2007.

22. J. T. Santini, Jr., M. J. Cima, and R. Langer, "A controlled-release microchip," Nature, vol. 397, pp. 335-338, 1999.

23. P. Y. Li, T. K. Givrad, D. P. Holschneider, J. M. Maarek, and E. Meng, "A perylene mems electrothermal valve," Journal of Microelectromechanical Systems, 2009, submitted for publication.

24. P. Y. Li, T. K. Givrad, D. P. Holschneider, J. M. Maarek, and E. Meng, "A wirelessly-activated perylene electrothermal valve for mapping brain function in freely moving subjects," in Hilton Head 2008, Hilton Head Island, South Carolina, 2008, pp. 32-35.

25. A. Nisar et al., MEMS-based micropumps in drug delivery and biomedical applications Sensors Actuators B Chem. (2008).

26. R. Lo, P. Y. Li, S. Saati, R. Agrawal, M. S. Humayun, and E. Meng, "A refillable microfabricated drug delivery device for treatment of ocular diseases," Lab on a Chip, vol. 8, pp. 1027-1030, 2008.

27. S. A. Warren, Medtronic Gains Approval of First Artificial Pancreas Device System with Threshold Suspend Automation, Medtronic, Minneapolis October, 2014.

28. B Fox, Cade, Hariharasudhan D Chirra, and Tejal A Desai. "Planar bioadhesive microdevices: a new technology for oral drug delivery." Current Pharmaceutical Biotechnology 15, no. 7 (2014): 673-683.

29. Tang, Rongbiao, Wei-Xia Li, Wei Huang, Fuhua Yan, Wei-Min Chai, Guo-Yuan Yang, and Ke-Min Chen. "CO2-based in-line phase contrast imaging of small intestine in mice." Scientific Reports 3 (2013): 2313.

30. Tao, Sarah L., and Tejal A. Desai. "Gastrointestinal patch systems for oral drug delivery." Drug Discovery Today 10, no. 13 (2005): 909-915.

31. Tao, Sarah L., and Tejal A. Desai. "Microfabrication of multilayer, asymmetric, polymeric devices for drug delivery." Advanced Materials 17, no. 13 (2005): 1625-1630.

32. S. N. Shivappriya, R. Dhivyapraba, A. Kalaiselvi, M. Alagumeenakshi. Telemedicine Approach for Patient Monitoring System using IOT. Research J. Engineering and Tech. 2017; 8(3): 233-236.

33. Sweta Bhattacharya. A Review of the Application of Automation Technologies in Healthcare Domain. Research J. Pharm. and Tech 2016; 9(12): 2343-2348.

34. S. Krishnakumar, K. Monika, Brite Jose John, Nevin Samuel. Automatic Ingestion Monitoring Device for Diet Control. Research J. Pharm. and Tech. 2017; 10(7): 2173-2178.

35. Syed Shameem, G. R. K. Prasad, Muzamilparvez. M, U. Reshmi, G. Harshitha, K. Haritha. Design and FEM model Analysis of MEMS cantilever structure for detection of Colon Cancer using Mass sensing. Research J. Pharm. and Tech. 2019; 12(9): 4250-4254.

36. Ramandeep Kaur, J N Sharma. Deflection in Micro-Scale Thermoelastic Simply-Supported Beams due to Patch Loading. Research J. Science and Tech. 2013: 5(1): 153-159.

37. Shinde. G.S., Prasad Kumbhar, Jadhav. R.S., Vikhe. D. N. Monoclonal Antibodies as a Site Specific Particulate Drug Delivery System: A Review. Asian Journal of Pharmaceutical Analysis. 2022; 12(4): 286-2.

38. Akhil Gupta, Anuj Mittal , Alok Kumar Gupta. Colon Targeted Drug Delivery Systems – A Review. Asian J. Pharm. Res. 2011; 1(2): 25-33.

39. Hiral A. Makadia, Ami Y. Bhatt, Ramesh B. Parmar, Ms. Jalpa S. Paun, H.M. Tank. Self-nano Emulsifying Drug Delivery System (SNEDDS): Future Aspects. Asian J. Pharm. Res. 2013; 3(1): 20-26.

40. Kumbhar Swapnil, Salunkhe Vijay , Magdum Chandrakant. Targeted Drug Delivery: A Backbone for Cancer Therapy. Asian J. Pharm. Res. 2013; 3(1): 40-46.

41. Kshitij B. Makeshwar, Suraj R. Wasankar. Niosome: a Novel Drug Delivery System. Asian J. Pharm. Res. 3(1): Jan.-Mar. 2013; Page 15-19. Asian J. Pharm. Res. 2013; 3(1): 15-19.

42. Girjesh Vishwakarma, Aakash Singh Panwar, Nirmal Dongre. Emulgel: A Novel Technique for Transdermal Drug Delivery. Research Journal of Topical and Cosmetic Sciences. 2023; 14(1): 20-8.

43. Diksha K. Nunse, Rohini N. Jadhav, Amol S. Deshmukh. Cream as a Drug Delivery System for Topical Diseases. Research Journal of Topical and Cosmetic Sciences. 2022; 13(1): 35-3.

Received on 29.03.2025 Revised on 03.07.2025

Accepted on 08.10.2025 Published on 10.12.2025

Available online from December 26, 2025

International Journal of Technology. 2025; 15(2):82-90.

DOI: 10.52711/2231-3915.2025.00015

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License. Creative Commons License.